August 11, 2023 12:22 PM EDT

Pharma companies look to tap medical social influencers in new agency partnership

Beth Snyder Bulik

Senior Editor

Collectively referred to as MedTwitter, Doctor Instagram or MedTok, they’re the trendy healthcare professional influencers on social media platforms. And some pharma companies are eager …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pharma companies look to tap medical social influencers in new agency partnership

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Biotech VC firm outlines plans for $100M fund

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development

Phar­ma com­pa­nies look to tap med­ical so­cial in­flu­encers in new agency part­ner­ship

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

Biotech VC firm out­lines plans for $100M fund

Sanofi's BTK in­hibitor again slows MS pro­gres­sion, but liv­er en­zymes con­tin­ue to be tricky

Lex­i­con's pres­i­dent to step down as de­ci­sion date looms; Sarep­ta wel­comes Lil­ly, GSK vet to board

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

Pharma companies look to tap medical social influencers in new agency partnership

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Biotech VC firm outlines plans for $100M fund

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development